vs
Side-by-side financial comparison of Protalix BioTherapeutics, Inc. (PLX) and Presurance Holdings, Inc. (PRHI). Click either name above to swap in a different company.
Protalix BioTherapeutics, Inc. is the larger business by last-quarter revenue ($9.1M vs $5.7M, roughly 1.6× Presurance Holdings, Inc.). Protalix BioTherapeutics, Inc. runs the higher net margin — -60.3% vs -369.2%, a 308.8% gap on every dollar of revenue. On growth, Protalix BioTherapeutics, Inc. posted the faster year-over-year revenue change (-49.9% vs -61.4%). Over the past eight quarters, Protalix BioTherapeutics, Inc.'s revenue compounded faster (-6.7% CAGR vs -44.7%).
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
PLX vs PRHI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $9.1M | $5.7M |
| Net Profit | $-5.5M | $-17.0M |
| Gross Margin | 49.4% | — |
| Operating Margin | -51.1% | -322.7% |
| Net Margin | -60.3% | -369.2% |
| Revenue YoY | -49.9% | -61.4% |
| Net Profit YoY | -184.8% | 32.9% |
| EPS (diluted) | $-0.06 | $-1.40 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.1M | $5.7M | ||
| Q3 25 | $17.9M | $6.8M | ||
| Q2 25 | $15.7M | $16.1M | ||
| Q1 25 | $10.1M | $15.9M | ||
| Q4 24 | $18.2M | $14.7M | ||
| Q3 24 | $18.0M | $16.0M | ||
| Q2 24 | $13.5M | $17.9M | ||
| Q1 24 | — | $18.6M |
| Q4 25 | $-5.5M | $-17.0M | ||
| Q3 25 | $2.4M | $-4.0M | ||
| Q2 25 | $164.0K | $2.1M | ||
| Q1 25 | $-3.6M | $522.0K | ||
| Q4 24 | $6.5M | $-25.4M | ||
| Q3 24 | $3.2M | $52.8M | ||
| Q2 24 | $-2.2M | $-4.0M | ||
| Q1 24 | — | $74.0K |
| Q4 25 | 49.4% | — | ||
| Q3 25 | 53.4% | — | ||
| Q2 25 | 62.5% | — | ||
| Q1 25 | 19.1% | — | ||
| Q4 24 | 78.7% | — | ||
| Q3 24 | 53.4% | — | ||
| Q2 24 | 29.8% | — | ||
| Q1 24 | — | — |
| Q4 25 | -51.1% | -322.7% | ||
| Q3 25 | 11.9% | -42.7% | ||
| Q2 25 | 7.5% | -22.6% | ||
| Q1 25 | -41.0% | -27.9% | ||
| Q4 24 | 39.6% | -177.1% | ||
| Q3 24 | 22.2% | -45.8% | ||
| Q2 24 | -18.0% | -24.3% | ||
| Q1 24 | — | 2.7% |
| Q4 25 | -60.3% | -369.2% | ||
| Q3 25 | 13.2% | -58.2% | ||
| Q2 25 | 1.0% | 12.7% | ||
| Q1 25 | -35.8% | 3.3% | ||
| Q4 24 | 35.6% | -172.4% | ||
| Q3 24 | 18.0% | 329.6% | ||
| Q2 24 | -16.4% | -22.1% | ||
| Q1 24 | — | 0.4% |
| Q4 25 | $-0.06 | $-1.40 | ||
| Q3 25 | $0.03 | $-0.32 | ||
| Q2 25 | $0.00 | $0.17 | ||
| Q1 25 | $-0.05 | $0.04 | ||
| Q4 24 | $0.10 | $-2.08 | ||
| Q3 24 | $0.03 | $4.32 | ||
| Q2 24 | $-0.03 | $-0.32 | ||
| Q1 24 | — | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $14.7M | $52.1M |
| Total DebtLower is stronger | — | $12.2M |
| Stockholders' EquityBook value | $48.2M | $9.0M |
| Total Assets | $82.3M | $239.3M |
| Debt / EquityLower = less leverage | — | 1.36× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $14.7M | $52.1M | ||
| Q3 25 | $13.6M | $62.3M | ||
| Q2 25 | $17.9M | $58.3M | ||
| Q1 25 | $19.5M | $52.3M | ||
| Q4 24 | $19.8M | $48.8M | ||
| Q3 24 | $27.4M | $53.6M | ||
| Q2 24 | $23.4M | $33.0M | ||
| Q1 24 | — | $41.0M |
| Q4 25 | — | $12.2M | ||
| Q3 25 | — | $12.1M | ||
| Q2 25 | — | $12.1M | ||
| Q1 25 | — | $12.0M | ||
| Q4 24 | — | $11.9M | ||
| Q3 24 | — | $16.5M | ||
| Q2 24 | — | $24.8M | ||
| Q1 24 | — | $24.9M |
| Q4 25 | $48.2M | $9.0M | ||
| Q3 25 | $52.9M | $25.3M | ||
| Q2 25 | $49.9M | $28.2M | ||
| Q1 25 | $45.2M | $25.6M | ||
| Q4 24 | $43.2M | $21.5M | ||
| Q3 24 | $32.4M | $49.1M | ||
| Q2 24 | $28.6M | $-1.2M | ||
| Q1 24 | — | $2.6M |
| Q4 25 | $82.3M | $239.3M | ||
| Q3 25 | $82.3M | $285.0M | ||
| Q2 25 | $78.5M | $283.3M | ||
| Q1 25 | $73.9M | $277.1M | ||
| Q4 24 | $73.4M | $281.7M | ||
| Q3 24 | $61.6M | $299.9M | ||
| Q2 24 | $91.5M | $292.9M | ||
| Q1 24 | — | $301.1M |
| Q4 25 | — | 1.36× | ||
| Q3 25 | — | 0.48× | ||
| Q2 25 | — | 0.43× | ||
| Q1 25 | — | 0.47× | ||
| Q4 24 | — | 0.55× | ||
| Q3 24 | — | 0.34× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 9.75× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $2.0M | $-43.9M |
| Free Cash FlowOCF − Capex | $1.6M | — |
| FCF MarginFCF / Revenue | 17.8% | — |
| Capex IntensityCapex / Revenue | 4.4% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-13.6M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.0M | $-43.9M | ||
| Q3 25 | $-3.7M | $-681.0K | ||
| Q2 25 | $-5.2M | $-2.8M | ||
| Q1 25 | $-5.1M | $-15.3M | ||
| Q4 24 | $4.0M | $-32.7M | ||
| Q3 24 | $4.1M | $-10.7M | ||
| Q2 24 | $-3.6M | $-10.1M | ||
| Q1 24 | — | $8.2M |
| Q4 25 | $1.6M | — | ||
| Q3 25 | $-4.2M | — | ||
| Q2 25 | $-5.7M | — | ||
| Q1 25 | $-5.4M | — | ||
| Q4 24 | $3.6M | — | ||
| Q3 24 | $4.0M | — | ||
| Q2 24 | $-3.8M | — | ||
| Q1 24 | — | — |
| Q4 25 | 17.8% | — | ||
| Q3 25 | -23.7% | — | ||
| Q2 25 | -36.2% | — | ||
| Q1 25 | -53.0% | — | ||
| Q4 24 | 19.6% | — | ||
| Q3 24 | 22.4% | — | ||
| Q2 24 | -28.1% | — | ||
| Q1 24 | — | — |
| Q4 25 | 4.4% | — | ||
| Q3 25 | 2.8% | — | ||
| Q2 25 | 2.8% | — | ||
| Q1 25 | 3.0% | — | ||
| Q4 24 | 2.3% | — | ||
| Q3 24 | 0.5% | — | ||
| Q2 24 | 1.3% | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | -1.58× | — | ||
| Q2 25 | -31.91× | -1.34× | ||
| Q1 25 | — | -29.23× | ||
| Q4 24 | 0.61× | — | ||
| Q3 24 | 1.27× | -0.20× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 110.47× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
PRHI
Segment breakdown not available.
